Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06008483
To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects with one or more solid tumor(s) in the bone or metastatic solid tumors to the bone that are visible on bone scan.
Overview
A Dose Finding Study of CycloSam® (153-Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewing's Sarcoma, and Other Solid Tumor(s) to the Bone All Eligible)
Sponsor
QSAM Therapeutics, Inc.
Phase
Phase 1
Contacts
Clinical Trials Team
clinicaltrials@qsambio.com
512-343-4558
ClinicalTrials.gov
NCT06008483Drug / Compound
Isotope(s):
SAMARIUM-153
Radioisotope: Sm153
Theranostic Role: Therapeutic
T1/2 (Half-Life): 1.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Max 808 keV Gamma: 103 keV (28%)
Range: 0.6 mm
Decay Daughters: Eu153 (Stable)
Status: FDA Approval: QUADRAMET® (1997)
Target(s):
Share your feedback
Help us improve your experience